Exton Michael purchased $50K of LXRX

Exton Michael (Chief Executive Officer) purchased 30,064 shares of LEXICON PHARMACEUTICALS, INC. (LXRX) at $1.66 on 2026-11-06.

Original reporting
SEC EDGAR · Exton Michael
Published Nov 9, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXRX
Bullish
high confidence
Mentioned
$LXRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXRXBullishLow
01

Why it matters

The $50K purchase is modest and unlikely to move the stock significantly, but it adds a data point for monitoring insider sentiment.

02

Market read

Small insider buy; limited trading relevance but useful for sentiment tracking.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market filing on 2026‑11‑09

Background

Form 4 filings disclose insider trades; investors watch them for signals of confidence.

Company-level read

Ticker impact

$LXRXBullishHigh confidence
Context

CEO Michael Exton bought 30,064 shares for $49,999, increasing his stake to 328,496 shares.

Expected impact

potential modest upside as market interprets the buy as a positive signal

Evidence & confidence

The purchase is a primary Form 4 filing, but the amount is small; any price effect is likely limited.

Market effects

minimal impact on biotech sector

none

none

Counterpoint

The purchase could be routine portfolio rebalancing, not a strong endorsement.

Key entities

  • Lexicon Pharmaceuticals, Inc.

    Biopharmaceutical company developing therapies for rare diseases.

  • Michael Exton

    Chief Executive Officer of Lexicon Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXRXMed

What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call

Lexicon Pharmaceuticals (LXRX) reported Q3 earnings, delaying ZYNQUISTA's diabetes application resubmission to Q1 2027 due to data preparation. The company presented preclinical obesity findings for pilavapadin and received a $10M milestone payment from Novo Nordisk. R&D expenses fell to $16.2M, while cash reserves stood at $183.2M.

$LXRXMed

Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data

Lexicon Pharmaceuticals (LXRX) reported Q3 2026 revenues of $11.3M, including a $10M milestone from Novo Nordisk. Key updates: Phase 3 Sonata HCM trial data expected Q1 2027, LX-9851 program advancing, and positive preclinical obesity data for pilavapidin. Net loss was $14.0M, or $0.03 per share, with $183.2M in cash. The company highlighted upcoming milestones, including the Sonata HCM data readout and Zynquista NDA resubmission in Q1 2027.

$LXRXMed

Lexicon (LXRX) Q3 2026 Earnings Call Transcript

Lexicon (LXRX) reported Q3 2026 progress, including completion of patient enrollment in the phase III SONATA-HCM study for HCM, with top-line results expected in Q1 2027. The company also made strides in resubmitting the NDA for ZYNQUISTA in type 1 diabetes, supported by new safety data from the STENO1 study, aiming for resubmission in Q1 2027.

$LXRXMed

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled…

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resu